Lilly Expands Affordability Options with Two Additional Non-Branded Options and Lilly Insulin Value Program

This article was provided and sponsored by Eli Lilly and Company

Lilly is helping people living with diabetes manage the cost of insulin with affordability solutions. In response to the COVID-19 crisis, Lilly introduced the Lilly Insulin Value Program, allowing anyone with commercial insurance, or without insurance, to fill their monthly prescription of Lilly insulin for $35 with a co-pay card. People can access this program by calling the Lilly Diabetes Solution Center at (833) 808-1234.

Additionally, non-branded versions of Humalog^® Mix75/25^™ KwikPen^® (insulin lispro protamine and insulin lispro injectable suspension 100 units/mL) and Humalog^® Junior KwikPen^® (insulin lispro injection 100 units/mL) are available for order in pharmacies. These non-branded insulin options are identical to the branded versions, with different packaging and a 50 percent lower list price of $265.20 for a package of five KwikPens. With these additions, Lilly has three non-branded insulin options. The company’s first non-branded insulin, Insulin Lispro Injection 100 units/mL (U-100), launched in 2019.

These non-branded insulin options are available to help people who may be struggling to pay for their insulin, including those who use government insurance and are unable to use the savings cards in our program.

Any pharmacy that does not stock the non-branded insulins can place an order and expect delivery in 1-2 days. All major U.S. wholesalers are distributing these insulins.

People with low co-pays through their insurance plan will still be able to access the branded versions. A pharmacist can help people determine which option will have the lowest out-of-pocket cost for them, depending on their insurance coverage.

With many individuals financially affected by the COVID-19 crisis, Lilly wants to remind people of cost-saving options for insulin, especially for those with no or limited income.

Pharmacists can direct anyone who needs help affording their Lilly insulin to call the Lilly Diabetes Solution Center at 833-808-1234, Monday-Friday to learn about affordability options. For people with an urgent need for Lilly insulin and nowhere else to turn, the Lilly Diabetes Solution Center can provide immediate help. Representatives can answer questions about whether a non-branded insulin, the Lilly Insulin Value Program or another affordability option, will provide the lowest out-of-pocket-cost for someone.

The solution center provides several ways to receive significant savings on Lilly insulin, including point-of-sale savings, information about obtaining Lilly insulin at free clinics, and more.

Terms, conditions, and limitations apply to the co-pay cards. Not available to those patients with government insurance such as Medicaid, Medicare, Medicare Part D, TRICARE^®/CHAMPUS, Medigap, DoD, or any State Patient or Pharmaceutical Assistance Program.

INDICATIONS AND IMPORTANT SAFETY INFORMATION FOR HUMALOG BRAND OF INSULINS AND LILLY’S NON-BRANDED INSULIN LISPRO PRODUCTS

Indications

Humalog (100 units/mL and 200 units/mL) and Insulin Lispro Injection (100 units/mL) are indicated to improve glycemic control in adults and children with diabetes mellitus. Humalog Mix75/25, Humalog Mix50/50 (insulin lispro protamine and insulin lispro injectable suspension, 100 units/mL) and Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25 (100 units/mL) are indicated to improve glycemic control in patients with diabetes mellitus.

Limitations of Use

The proportions of rapid-acting and intermediate-acting insulins in Humalog Mix75/25, Humalog Mix50/50, and Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25 are fixed and do not allow for basal versus prandial dose adjustments.

IMPORTANT SAFETY INFORMATION FOR HUMALOG BRAND OF INSULINS AND LILLY INSULIN INJECTABLE PRODUCTS

Contraindications

Humalog, Insulin Lispro Injection, Humalog Mix75/25, Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25, and Humalog Mix50/50 are contraindicated during episodes of hypoglycemia and in patients who are hypersensitive to these insulins or any of their excipients.

Warnings and Precautions

Never share a Humalog, Insulin Lispro Injection, Humalog Mix75/25, Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25, or Humalog Mix50/50 prefilled pen, cartridge, reusable pen compatible with Lilly 3 mL cartridges, or syringe between patients, even if the needle is changed. Patients using vials must never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens.

Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen: Changes in insulin strength, manufacturer, type, injection site, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. Any changes in insulin regimen should be made cautiously under close medical supervision and the frequency of blood glucose monitoring should be increased. Due to reports of hyperglycemia and hypoglycemia, advise patients who have repeatedly injected into areas of lipodystrophy or localized cutaneous amyloidosis to change the injection site to unaffected areas and closely monitor blood glucose. For patients with type 2 diabetes, dosage adjustments of concomitant antidiabetic products may be needed.

Hypoglycemia: Severe hypoglycemia may be life threatening and can cause seizures or death. Hypoglycemia is the most common adverse reaction of Humalog, Insulin Lispro Injection, Humalog Mix75/25, Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25, and Humalog Mix50/50. Monitor blood glucose and increase monitoring frequency with changes to insulin dosage, use with glucose-lowering medications, meal pattern, physical activity; in patients with renal or hepatic impairment; and in patients with hypoglycemia unawareness.

Hypoglycemia Due to Medication Errors: Instruct patients to always check the insulin label before each injection to avoid medication errors. Humalog U-200 should not be transferred from the Humalog KwikPen to a syringe as overdose and severe hypoglycemia can occur.

Hypersensitivity Reactions: Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with Humalog, Insulin Lispro Injection, Humalog Mix75/25, Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25, and Humalog Mix50/50. If hypersensitivity reactions occur, discontinue the use of insulin and treat per standard of care until signs and symptoms resolve.

Hypokalemia: Hypokalemia may be life threatening. Insulins, including Humalog, Insulin Lispro Injection, Humalog Mix75/25, Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25, and Humalog Mix50/50, cause a shift in potassium from the extracellular to intracellular space possibly leading to hypokalemia, which, if untreated, may result in respiratory paralysis, ventricular arrhythmia, and death. Monitor potassium levels in patients at risk for hypokalemia (e.g., patients using potassium-lowering medications or medications sensitive to serum potassium concentrations).

Fluid Retention and Heart Failure with Concomitant Use of PPAR-gamma Agonists: Thiazolidinediones (TZDs), which are PPAR-gamma agonists, can cause dose-related fluid retention, particularly when used in combination with insulin, including Humalog, Insulin Lispro Injection, Humalog Mix75/25, Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25, and Humalog Mix50/50. This may lead to or exacerbate heart failure. Observe patients for signs and symptoms of heart failure and consider discontinuation or dose reduction of the PPAR-gamma agonist.

Hyperglycemia and Ketoacidosis Due to Insulin Pump Device Malfunction: Malfunction of the insulin pump device, infusion set, or insulin degradation can rapidly lead to hyperglycemia and ketoacidosis. Patients using subcutaneous insulin infusion pumps must be trained to administer insulin by injection and have alternate insulin therapy available in case of pump failure.

• Adverse Reactions

Adverse reactions associated with Humalog, Insulin Lispro Injection, Humalog Mix75/25, Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25, and Humalog Mix50/50 include hypoglycemia, hypokalemia, allergic reactions, injection-site reactions, lipodystrophy, pruritus, rash, weight gain, and peripheral edema.

• Drug Interactions

Some medications may alter glucose metabolism, insulin requirements, and the risk for hypoglycemia or hyperglycemia. Signs of hypoglycemia may be reduced or absent in patients taking anti-adrenergic drugs. Particularly close monitoring may be required.

Click to access Humalog Full Prescribing Information, Insulin Lispro Injection Full Prescribing Information, Humalog Mix75/25 Full Prescribing Information, Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25 Full Prescribing Information and Humalog Mix50/50 Full Prescribing Information.

HI BOI SP U100 75/25 HCP ISI 10JAN2020

Humalog^®, KwikPen^®, Humalog^® Mix50/50^TM, and Humalog^® Mix75/25^TM are trademarks or registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

TRICARE^® is a registered trademark owned by the U.S. Department of Defense.

# # #

PP-LD-US-2135 07/2020 ©Lilly USA, LLC 2020. All rights reserved.